-
Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations.
AJR Am J Roentgenol. 1992 Aug;159(2):287-94
PMID: 1632342
-
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.
Cancer. 2008 Oct 1;113(7):1521-6
PMID: 18726992
-
Rethinking screening for breast cancer and prostate cancer.
JAMA. 2009 Oct 21;302(15):1685-92
PMID: 19843904
-
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7
PMID: 10430922
-
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Breast Cancer Res Treat. 2009 Jan;113(2):357-70
PMID: 18324472
-
Estimating lifetime and age-conditional probabilities of developing cancer.
Lifetime Data Anal. 1998;4(2):169-86
PMID: 9658774
-
Screening for breast cancer: an update for the U.S. Preventive Services Task Force.
Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-42
PMID: 19920273
-
Differences in risk factors for breast cancer molecular subtypes in a population-based study.
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43
PMID: 17372238
-
Estimating age conditional probability of developing disease from surveillance data.
Popul Health Metr. 2004 Jul 27;2(1):6
PMID: 15279675
-
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA. 2006 Jun 21;295(23):2727-41
PMID: 16754727
-
Concordance among gene-expression-based predictors for breast cancer.
N Engl J Med. 2006 Aug 10;355(6):560-9
PMID: 16899776
-
Meta-analysis of BRCA1 and BRCA2 penetrance.
J Clin Oncol. 2007 Apr 10;25(11):1329-33
PMID: 17416853
-
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
PMID: 12829800
-
Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace.
Am J Public Health. 2003 Oct;93(10):1685-8
PMID: 14534222
-
On mammography--more agreement than disagreement.
N Engl J Med. 2009 Dec 24;361(26):2499-501
PMID: 19940286
-
Epidemiology of basal-like breast cancer.
Breast Cancer Res Treat. 2008 May;109(1):123-39
PMID: 17578664
-
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
PMID: 17438091
-
Performance of common genetic variants in breast-cancer risk models.
N Engl J Med. 2010 Mar 18;362(11):986-93
PMID: 20237344
-
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Cancer. 2007 May 1;109(9):1721-8
PMID: 17387718
-
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
PLoS Med. 2010 May 25;7(5):e1000279
PMID: 20520800
-
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
PMID: 16288118
-
Molecular portraits of human breast tumours.
Nature. 2000 Aug 17;406(6797):747-52
PMID: 10963602
-
Triple-negative breast cancer: clinical features and patterns of recurrence.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
PMID: 17671126
-
Migraine history and breast cancer risk among postmenopausal women.
J Clin Oncol. 2010 Feb 20;28(6):1005-10
PMID: 20100960
-
Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer.
J Clin Oncol. 2009 Nov 10;27(32):5312-8
PMID: 19738113
-
Triple-negative breast cancers are increased in black women regardless of age or body mass index.
Breast Cancer Res. 2009;11(2):R18
PMID: 19320967
-
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
J Clin Oncol. 2009 Sep 20;27(27):4515-21
PMID: 19704069
-
Breast cancer. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw. 2009 Feb;7(2):122-92
PMID: 19200416
-
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
J Clin Oncol. 2009 Jan 10;27(2):220-6
PMID: 19047281
-
Age-related crossover in breast cancer incidence rates between black and white ethnic groups.
J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14
PMID: 19066264
-
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
Breast Cancer Res Treat. 2008 Sep;111(1):27-44
PMID: 17922188
-
The lifetime risk of developing breast cancer.
J Natl Cancer Inst. 1993 Jun 2;85(11):892-7
PMID: 8492317
-
Age-conditional probabilities of developing cancer.
Stat Med. 2003 Jun 15;22(11):1837-48
PMID: 12754719
-
Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.
JAMA. 2010 Jul 28;304(4):426-34
PMID: 20664043
-
Assessing women at high risk of breast cancer: a review of risk assessment models.
J Natl Cancer Inst. 2010 May 19;102(10):680-91
PMID: 20427433
-
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
Breast Cancer Res Treat. 2010 Nov;124(1):133-40
PMID: 20697801
-
The descriptive epidemiology of second primary breast cancer.
Epidemiology. 2003 Sep;14(5):552-8
PMID: 14501270
-
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
J Clin Oncol. 2008 Sep 10;26(26):4282-8
PMID: 18779615
-
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
JAMA. 2006 Jun 7;295(21):2492-502
PMID: 16757721
-
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86
PMID: 18664548
-
Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women.
Breast Cancer Res Treat. 2008 Oct;111(3):405-10
PMID: 18026834
-
Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer.
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):479-85
PMID: 19190139
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
J Clin Oncol. 2008 Mar 10;26(8):1275-81
PMID: 18250347
-
Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Breast J. 2009 Nov-Dec;15(6):593-602
PMID: 19764994